2-Hydroxybutyric acid
|
Basic information |
| Metabolite name | 2-Hydroxybutyric acid |
 | HMDB0000008 |
 |
C05984 |
 |
440864 |
| Synonyms | (S)-2-Hydroxybutanoic acid; |
| No. of studies | 12 |
|
Basic information |
| Metabolite name | 2-Hydroxybutyric acid |
| HMDB0000008 |
|
C05984 |
|
440864 |
| Synonyms | (S)-2-Hydroxybutanoic acid; |
| No. of studies | 12 |
|
Relationship between 2-Hydroxybutyric acid and depression (count: 12) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M018 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M042 | Type3 | fluoxetine group vs. control group | Cerebrospinal fluid | Rhesus monkey | Down |
| Study M058 | Type1 | depressed HBV-infected patients group vs. control group and non-depressed HBV-infected group | Urine | Human | Up |
| Study M094 | Type1 | PSD group vs. stroke and control group | Urine | Human | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Amygdala | Cynomolgus monkey | Down |
| Study M1105 | Type1 | psychological stress group vs. control group | Faece | C57BL/6 J mouse | Down |
| Study M1143 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M1143 | Type2 | MDD group, after 2-week escitalopram treatment vs. baseline | Plasma | Human | Down |
| Study M1143 | Type2 | MDD group, after 12-week escitalopram treatment vs. baseline | Plasma | Human | Down |
| Study M115 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M181 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Ventral hippocampus | C57BL/6 J mouse | Down |
| Study M748 | Type1 | short-day group vs. long-day group | Plasma | C57BL/6 J mouse | Down |
| Study M911 | Type1 | CUS group vs. control group | Serum | Sprague-Dawley rat | Down |